Hematology

Latest News

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

By Jared Kaltwasser

April 15th 2025

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS

By Mary Caffrey
Caspian Oliai, MD, MS

April 11th 2025

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

By Jared Kaltwasser

April 10th 2025

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com

Immune Microenvironment a Key Target in CLL

By Jared Kaltwasser

April 8th 2025

Health equity concept | image credit: VectorMine - stock.adobe.com

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

By Kyle Munz
Ajai Chari, MD

April 7th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

More News

A New Target for CAR T Cells Achieves Remission in Resistant Pediatric B-ALL

November 22nd 2017

A New Target for CAR T Cells Achieves Remission in Resistant Pediatric B-ALL

Surabhi Dangi-Garimella, PhD

An early-stage trial in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) has found that modifying the chimeric antigen receptor (CAR) T cells to target the CD22 receptor achieved remission.

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

November 15th 2017

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

Cyclin-dependent kinase 4/6 inhibitors may have proven benefits for treating metastatic breast cancer, but the therapies are associated with hematological toxicities and febrile neutropenia.

Maximal Tolerated Dose of Hydroxyurea Supported in Children With Sickle Cell Anemia

November 14th 2017

Maximal Tolerated Dose of Hydroxyurea Supported in Children With Sickle Cell Anemia

Recently reported results from Hydroxyurea Study of Long-Term Effects (HUSTLE) support the use of hydroxyurea in children, and indicate that a preferred dosing strategy should target an HbF endpoint of greater than 20%.

Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC

November 8th 2017

Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC

Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.

Study Investigates the Effects of GSK-3 Inhibition to Improve Understanding of Leukemia

November 7th 2017

Study Investigates the Effects of GSK-3 Inhibition to Improve Understanding of Leukemia

Alison Rodriguez

Research into GSK-3 inhibition in cells may have implications for leukemia treatment.

FDA Accepts BLA For Bayer's Proposed Hemophilia A Treatment

November 1st 2017

FDA Accepts BLA For Bayer's Proposed Hemophilia A Treatment

Bayer has announced the FDA’s acceptance of its Biologics License Application (BLA) for BAY94-9027 for the treatment of hemophilia A in adults and adolescents aged 12 years or older.

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

November 1st 2017

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

Jaime Rosenberg

Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

October 29th 2017

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

Alison Rodriguez

Results of the Phase 3 ARROW trial revealed that patiehts with refractory multiple myeloma can live up to 3.6 months longer, without their disease worsening, when Kyprolis (carfilzomib) is administered once-weekly at the 70 mg/m2 dose with dexamethasone rather than Kyprolis administered twice-weekly at the 27 mg/m2 dose with dexamethasone, according to Amgen.

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

October 28th 2017

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

Alison Rodriguez

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez

Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.

October 20th 2017

Study: CAR T-Cell Therapy Highly Effective in High-Risk Chronic Lymphocytic Leukemia

CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.

October 17th 2017

Looking Ahead at the Specialty Drug Pipeline After an Active Year of Approvals

Christina Mattina

Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.

October 16th 2017

St. Jude Study Questions Efficacy of the Flu Vaccine in Children With Leukemia

Surabhi Dangi-Garimella, PhD

The study found that young patients with leukemia who have been vaccinated against the influenza virus are as susceptible to develop flu as their unvaccinated peers.

October 16th 2017

Pharmacy Team Engagement in Navigating the Revenue Cycle for High-Cost Medications in Patients With Cancer

Brandon R. Shank, PharmD, MPH, BCOP Phuoc Anh (Anne) Nguyen, PharmD, MS, BCPS Emily C. Pherson, PharmD, BCPS

With the clinical and financial implications of high-cost medications, and their impact on health system revenue, it is of utmost importance for all key stakeholders to be engaged in the complex revenue cycle.

October 13th 2017

Study: Body Fat Composition May Predict Poor Treatment Outcomes in Patients With Multiple Myeloma

A recent study found that excess body fat in the abdomen and pelvis may predict poor treatment response in patients with multiple myeloma.

October 13th 2017

In Conversation With a Pharmacist: Management of CAR T-Cell Treatment

Surabhi Dangi-Garimella, PhD

Evidence-Based OncologyTM sat down with Brandon R. Shank, PharmD, MPH, BCOP, clinical pharmacy specialist, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, to understand a pharmacist's role in administering chimeric antigen receptor (CAR) T cells.

October 12th 2017

Second Interim Analysis Suggests Carfilzomib Improves Survival in Multiple Myeloma

Alison Rodriguez

Following the phase 3 ENDEAVOR trial that compared 2 proteasome inhibitors-carfilzomib and bortezomib-in relapsed or refractory multiple myeloma patients, researchers conducted a second interim analysis to compare the overall survival between the 2 groups.

October 10th 2017

Study Finds Antibiotic Effective in Reducing Rate of Infection in Children With ALL

Alison Rodriguez

October 7th 2017

LLS Survey Shows Lack of Blood Cancer Awareness in the United States

Alison Rodriguez

A recent survey by The Leukemia & Lymphoma Society found that the majority of adults are surprised by the prevalence of blood cancers-specifically the prevalence of acute lymphocytic leukemia among children and young adults.

October 6th 2017

Report Analyzes Pipeline of Drugs for Treating Chemotherapy-Related Toxicities

Alison Rodriguez

A recent report, “Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017,” presents a summary of drugs in development to treat chemotherapy-related toxicities.

September 18th 2017

New CDC Report Provides Update on Incidence Rates of Pediatric ALL

Surabhi Dangi-Garimella, PhD

New results published in CDC’s Morbidity and Mortality Weekly Report have identified a surge in pediatric acute lymphoblastic leukemia (ALL) during the period 2001 to 2008, followed by stabilization during 2008 to 2014.

September 15th 2017

Copanlisib Receives Accelerated Approval for Relapsed Follicular Lymphoma

Christina Mattina

Patients with relapsed follicular lymphoma now have a new treatment option: copanlisib, a kinase inhibitor that was recently approved through the FDA’s accelerated approval process.

September 4th 2017

Healthy, but Still Hurting: Challenges of Cancer Survivorship

Laura Joszt, MA

The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.

September 1st 2017

A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin

The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.

September 1st 2017

5 Significant Developments With CAR-T Therapy

Surabhi Dangi-Garimella, PhD

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

August 25th 2017

Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial

Surabhi Dangi-Garimella, PhD

Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.

August 24th 2017

Study Finds HPV Vaccination Underutilized by Childhood Cancer Survivors

Surabhi Dangi-Garimella, PhD

A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.

August 21st 2017

FDA Approves Besponsa for Relapsed/Refractory Acute Lymphoblastic Leukemia

Alison Rodriguez

The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

August 14th 2017

Matching PROs With Medical Records to Assess Comorbidities in Prostate Cancer

Surabhi Dangi-Garimella, PhD

Patient reported data can be a reliable source of information to ascertain comorbidities in patients with prostate cancer, says JAMA Oncology study.

August 9th 2017

Results of Phase 2 Study Investigating Luspatercept in MDS

Alison Rodriguez

The results of a phase 2 study that explored the effects of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) were presented at the 22nd Congress of the European Hematology Association by Acceleron Pharma Inc. The company is developing the drug with Celgene.

...

19 20 21 22 23 24 25 26 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions